JP2013517773A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517773A5 JP2013517773A5 JP2012550162A JP2012550162A JP2013517773A5 JP 2013517773 A5 JP2013517773 A5 JP 2013517773A5 JP 2012550162 A JP2012550162 A JP 2012550162A JP 2012550162 A JP2012550162 A JP 2012550162A JP 2013517773 A5 JP2013517773 A5 JP 2013517773A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- chimeric protein
- heterologous antigen
- amino acids
- norovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 claims 24
- 108020001507 fusion proteins Proteins 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 21
- 235000001014 amino acid Nutrition 0.000 claims 16
- 229940024606 amino acid Drugs 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 16
- 108090000565 Capsid Proteins Proteins 0.000 claims 15
- 102100023321 Ceruloplasmin Human genes 0.000 claims 15
- 241001263478 Norovirus Species 0.000 claims 13
- 238000000034 method Methods 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000351643 Metapneumovirus Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29710910P | 2010-01-21 | 2010-01-21 | |
| US61/297,109 | 2010-01-21 | ||
| PCT/US2011/022094 WO2011091279A2 (en) | 2010-01-21 | 2011-01-21 | Targeted heterologous antigen presentation on calicivirus virus-like particles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000115A Division JP2016106101A (ja) | 2010-01-21 | 2016-01-04 | カリシウイルスウイルス様粒子上の標的化異種抗原提示 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013517773A JP2013517773A (ja) | 2013-05-20 |
| JP2013517773A5 true JP2013517773A5 (enExample) | 2014-03-13 |
Family
ID=44307607
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550162A Pending JP2013517773A (ja) | 2010-01-21 | 2011-01-21 | カリシウイルスウイルス様粒子上の標的化異種抗原提示 |
| JP2016000115A Pending JP2016106101A (ja) | 2010-01-21 | 2016-01-04 | カリシウイルスウイルス様粒子上の標的化異種抗原提示 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000115A Pending JP2016106101A (ja) | 2010-01-21 | 2016-01-04 | カリシウイルスウイルス様粒子上の標的化異種抗原提示 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8980275B2 (enExample) |
| EP (1) | EP2525816A4 (enExample) |
| JP (2) | JP2013517773A (enExample) |
| KR (1) | KR20120125627A (enExample) |
| CN (1) | CN102791286B (enExample) |
| AU (1) | AU2011207355B2 (enExample) |
| CA (1) | CA2787666A1 (enExample) |
| SG (1) | SG182636A1 (enExample) |
| WO (1) | WO2011091279A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE032422T2 (en) | 2006-09-29 | 2017-09-28 | Takeda Vaccines Inc | Norovirus vaccine preparations |
| CA2683977C (en) * | 2007-03-14 | 2017-04-25 | Ligocyte Pharmaceuticals, Inc. | A method of norovirus virus-like particle purification comprising ion exchange chromatography |
| SG10201601660YA (en) | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| AU2009279456B2 (en) * | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| SG182636A1 (en) * | 2010-01-21 | 2012-08-30 | Ligocyte Pharmaceuticals Inc | Targeted heterologous antigen presentation on calicivirus virus-like particles |
| EA029470B1 (ru) | 2011-07-11 | 2018-03-30 | Такеда Вэксинс, Инк. | Способ стимулирования формирования защитного иммунитета против норовируса |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| US9975923B2 (en) | 2013-03-15 | 2018-05-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
| WO2014145245A2 (en) * | 2013-03-15 | 2014-09-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus blockade epitopes |
| JP2015015931A (ja) * | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ウイルス様粒子を含む培養物の製造方法 |
| WO2015101666A1 (en) | 2014-01-03 | 2015-07-09 | Fundación Biofísica Bizkaia | VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF |
| WO2016160166A1 (en) * | 2015-03-30 | 2016-10-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic rsv polypeptides |
| JP6675185B2 (ja) * | 2015-11-30 | 2020-04-01 | 宏 半田 | 免疫誘導剤およびその製造方法 |
| US11141474B2 (en) * | 2016-05-04 | 2021-10-12 | Curevac Ag | Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof |
| CA3056812C (en) | 2017-03-23 | 2022-11-29 | Medicago Inc. | Norovirus fusion proteins and vlps comprising norovirus fusion proteins |
| CN107988240A (zh) * | 2017-12-20 | 2018-05-04 | 中国人民解放军南京军区南京总医院 | 鼠诺如病毒vp1蛋白病毒样颗粒表达、纯化及多克隆抗体制备 |
| AR117462A1 (es) * | 2018-12-20 | 2021-08-04 | Takeda Vaccines Inc | Vacuna contra norovirus, formulaciones y métodos |
| CN116063578A (zh) * | 2022-11-22 | 2023-05-05 | 中国医学科学院医学生物学研究所 | 一种以诺如病毒衍生的纳米颗粒作为疫苗平台的制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572862B1 (en) * | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| AU4851493A (en) * | 1992-09-07 | 1994-03-29 | Baylor College Of Medicine | Methods and reagents to detect and characterize norwalk and related viruses |
| KR100771402B1 (ko) | 1999-06-22 | 2007-10-30 | 국립감염증연구소장이 대표하는 일본국 | Ｓｒｓｖ 검출 킷트 |
| US8277819B2 (en) * | 2005-06-16 | 2012-10-02 | Children's Hospital Medical Center | Norovirus particle for use as an antiviral or vaccine |
| HUE032422T2 (en) * | 2006-09-29 | 2017-09-28 | Takeda Vaccines Inc | Norovirus vaccine preparations |
| AU2007304883B2 (en) * | 2006-10-04 | 2013-09-05 | The University Of Queensland | VLP based vaccine delivery system |
| US8486421B2 (en) * | 2009-06-09 | 2013-07-16 | Children's Hospital Medical Center | Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods for their making and use |
| SG182636A1 (en) * | 2010-01-21 | 2012-08-30 | Ligocyte Pharmaceuticals Inc | Targeted heterologous antigen presentation on calicivirus virus-like particles |
-
2011
- 2011-01-21 SG SG2012053807A patent/SG182636A1/en unknown
- 2011-01-21 KR KR1020127021082A patent/KR20120125627A/ko not_active Ceased
- 2011-01-21 CN CN201180013873.0A patent/CN102791286B/zh not_active Expired - Fee Related
- 2011-01-21 EP EP11735244.3A patent/EP2525816A4/en not_active Withdrawn
- 2011-01-21 US US13/574,756 patent/US8980275B2/en not_active Expired - Fee Related
- 2011-01-21 JP JP2012550162A patent/JP2013517773A/ja active Pending
- 2011-01-21 CA CA2787666A patent/CA2787666A1/en not_active Abandoned
- 2011-01-21 AU AU2011207355A patent/AU2011207355B2/en not_active Ceased
- 2011-01-21 WO PCT/US2011/022094 patent/WO2011091279A2/en not_active Ceased
-
2015
- 2015-02-09 US US14/617,576 patent/US20150252082A1/en not_active Abandoned
-
2016
- 2016-01-04 JP JP2016000115A patent/JP2016106101A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517773A5 (enExample) | ||
| Yong et al. | Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus | |
| JP2014532691A5 (enExample) | ||
| Hadj Hassine et al. | Virus‐like particles as powerful vaccination strategy against human viruses | |
| JP2015524422A5 (enExample) | ||
| JP2014507144A5 (ja) | 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物 | |
| MX346245B (es) | Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria. | |
| Lin et al. | Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens | |
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| JP2013533745A5 (enExample) | ||
| WO2008148104A8 (en) | Novel vlps derived from cells that do not express a viral matrix or core protein | |
| Valero-Pacheco et al. | Antibody persistence in adults two years after vaccination with an H1N1 2009 pandemic influenza virus-like particle vaccine | |
| JP2013523686A5 (enExample) | ||
| CA2863981A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
| MX2013013228A (es) | Particulas similares a virus y proceso para prepararlas. | |
| Bachmann et al. | Virus-like particles: a versatile and effective vaccine platform | |
| JP2023024998A5 (enExample) | ||
| JP2014519817A5 (enExample) | ||
| CN103525855A (zh) | 一种制备重组肠道病毒ev71型病毒样颗粒的方法 | |
| PE20100365A1 (es) | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion | |
| Raji et al. | Virus-like particles in poultry disease: an approach to effective and safe vaccination | |
| Yong et al. | Development of virus‐like particles‐based vaccines against coronaviruses | |
| JP2019506168A5 (enExample) | ||
| RU2022108149A (ru) | Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании | |
| HK1212708A1 (zh) | H1n1流感的計算優化的寬反應性抗原 |